Please ensure Javascript is enabled for purposes of website accessibility

Why BeiGene's Shares Jumped on Friday

By Jim Halley – Sep 17, 2021 at 1:17PM

Key Points

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Chinese pharmaceutical company is racking up approvals for its lead oncology drug, Brukinsa.

What happened

BeiGene (BGNE 3.83%), a Chinese pharmaceutical company, saw its shares rise more than 10% in early trading on Friday. The stock, which closed at $385.24 on Thursday, opened Friday at $422 a share, climbing as high as $426.56 in mid-morning trading. The stock is up more than 55% year to date.

A scientist works by a microscope.

IMAGE SOURCE: GETTY IMAGES

So what

The company has been on a roll lately with its lead oncology drug, Brukinsa (zanubrutinib). On Wednesday, BeiGene said that the Food and Drug Administration had granted accelerated approval to Brukinsa as a therapy for patients with relapsed or refractory marginal zone lymphoma who have already had at least one regimen of an anti-CD20-based antibody treatment. Anti-CD20 antibodies kill immune B-cells, which can cause inflammation.

It is the third FDA approval for the drug; previously it was cleared for use as a treatment for Waldenström's macroglobulinemia and mantle cell lymphoma in patients who had already received a prior therapy. BeiGene is also waiting to see if the FDA will approve Brukinsa's use as a therapy for chronic lymphocytic leukemia.

Plus, on Friday, the company announced that the European Medicines Agency's Committee for Medical Products for Human Use was recommending approval for Brukinsa to treat adults with Waldenström's macroglobulinemia who have already undergone treatment with a different therapy or for patients for whom chemotherapy was unsuitable.

Now what

Brukinsa is in a class of drugs that inhibit a protein called Bruton's tyrosine kinase (BTK), which is associated with various B-cell malignancies. If Brukinsa can show superior efficacy and safety to Imbruvica, the market's top-selling BTK inhibitor, that would be a big deal: AbbVie made $5.3 billion last year in revenue from Imbruvica.

BeiGene, a biotech company, reported $755.8 million in revenue through the first six months of 2021, up 542% year over year. That included revenue of $42.4 million from Brukinsa, compared to $7 million in the same period last year. However, BeiGene is still losing money, to the tune of $413.8 million through the first half of the year.

As Brukinsa's applications expand, though, so too will the drug's revenues, allowing BeiGene to fund its other clinical trials and giving it further potential for considerable growth.

Jim Halley owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

BeiGene Stock Quote
BeiGene
BGNE
$200.78 (3.83%) $7.40
AbbVie Stock Quote
AbbVie
ABBV
$165.99 (0.36%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.